Interferons (IFN) have offered considerable advances in the therapy of genital warts even those associated with cervical intraepithelial neoplasia (CIN); intralesional therapy either alone or in combination with other modalities such as cryosurgery and laser surgery provides improved clearing and cure of these often recalcitrant lesions. The purpose of this study was to evaluate the effectiveness of intralesional IFN therapy in patients with CIN associated with human papillomavirus (HPV) infection.
Methods
Beta-IFN was injected intra-perilesionally into the cervix in 41 patients with CIN associated with HPV infection.
Results
The regimen of 3 million international units (IU) injected intralesionally daily in the 1st week and 3 times a week in the 2nd and 3rd weeks for a total of 11 injections and a total dosage of 33 million IU yielded an 80 percent cure rate and may be more advantageous than other treatment options in certain instances. Cytocolposcopic and histologic examination was carried out before and after treatment and 24 lesions were also analyzed for type-specific papillomaviruses using in situ DNA hybridization. CIN disappeared in 33 patients 6 months after the end of therapy. Side effects of intralesional IFN therapy are dose related and for the most part readily tolerated.
Conclusions
Intralesional IFN proved to be effective treatment for CIN associated with HPV infection (cure rate: 80%) and well accepted because hospitalization is not required and no important side effects occur.
BiancaA.R., PalmieriG., AironeG.: Gli interferoni: ruolo e prospettive terapeutiche nei tumori solidi. In: Ruolo dei Modulatori della Risposta Biologica in Oncologia.Progressi in Oncologia Clinica, Edimes, Pavia1: 55–72, 1990.
2.
ChangE.H., JayF.T.: Physical, morphological and biochemical alteration in the membranes of akr mouse cells after interferon treatment.Proc. Natl. Acad. Sci. USA,1859–1863, 1978.
3.
CrumC.P., EgawaK., BarronB., FenoglioC.M., LevineR.V., RichartR.M.; Human papillomavirus infection (condyloma) of the cervix and cervical intraepithelial neoplasia. A histopathological and statistical analysis.Gynecol. Oncol., 15: 88–94, 1983.
4.
De PaloG., StefanenB., RilkeF., PilottiS., GhioneM.: Human fibroblast interferon in cervical and vulvar intraepithelial neoplasia associated with viral cytopathic effects. A pilot study.J. Reprod. Med., 30: 404, 1985.
5.
DjeuJ.Y., HerbermanR.B.: Augmentation of mouse natural killer activity and induction of interferon by tumor cells in vivo.J. Exp. Med., 151: 781–789, 1980.
6.
FallaniM.G., PennaC., SonniL., GordigianiR., CioffiM., CesarioL., MaggiorelliM., MarchionniM.: Trattamento della Condilomatosi genitale femminile con beta-interferone per via intramuscolare.Minerva Ginecol., 43: 595–599, 1991.
7.
FenoglioC.M.: viruses in the pathogenesis of cervical neoplasia.An update. Human Pathol., 13: 785–787, 1982.
8.
HanssonM., KiesslingR., AnderssonB.: Effect of interferon and interferon inducers on the NK sensitivity of normal mouse thymocytes.J. Immunol., 125: 2225–2231, 1987.
9.
HeronI., HollandM., BergK.: Enhanced expression of alfa-microglobulin and HLA antigen on lymphoid cells by interferon.Proc. Natl. Acad. Sci USA, 6215–6219, 1978.
10.
HsuC., ChooY.C., SetoW.H., PangS.W., TanC.Y., MeriganT.C., NgM.H.: Exfoliative cytology in the evaluation of interferon treatment of cervical intraepithelial neoplasia.Acta Cytol.28: 111–117, 1984.
11.
IkicD., BosnicN., SmerdelS.: Double-blind clinical study with human leucocyte interferon in therapy of condylomata acuminata.Proc. Symposium on Clinical Use of Interferon. Yugoslav Academy Sciences and Arts, Zagreb., 229–233, 1975.
12.
IkicD., KrusicJ., CopakK.: The use of human leucocyte interferon in patients with cervical cancer and basocellular cancer of the skin.Proc. Symposium on Clinical Use of Interferon. Yugoslav Academy Sciences and Arts, Zagreb, 240–245, 1975.
13.
IkicD., OrescanainM., KrusicJ.: Preliminary study of the effect of human leucocyte interferon on condylomata acuminata in women.Proc. Symposium on Clinical Use of Interferon. Yugoslav Academy Sciences and Arts, Zagreb, 223–227, 1975.
14.
IkicD., SingerZ., BeckM., SoosE., SipsO., JusicD.: Interferon treatment of uterina cervical precancerosis.J. Cancer Res. Clin. Oncol., 101: 303–308, 1981.
15.
KatajaV., SyrjanenK., MantyjarviR., VäyrynenM., SyrjänenS., SaarikoskiS., ParkkinenS., YliskoskiM., SalonenJ.T., CastrenO.: Prospective follow-up of cervical HPV infections: life table analysis of histopathological, cytological and colposcopic data.Eur. J. Epidemiol., 5: 1–7, 1989.
16.
MarchionniM., FallaniM.G., BraccoG.L., SonniL., CioffiM., MeiniL., GordigianiR., PennaC.: Management of human papillomavirous genital infection by β-interferon. Current research in Gynecology and Obstetrics.Third European Winter Conference in Gynecology and Obstetrics, Madonna di Campiglio, 1: 27–32, 1991, Italy.
17.
MitchellH., DrakeM., MedleyG.: Prospective evaluation of risk of cervical cancer after cytological evidence of human papillomavirus infection.Lancet, 1: 573–575, 1986.
18.
MurdochJ.B., CassidyL.J., FletcherK., CordinerJ.W., MacnabJ.C.M.: Histological and cytological evidence of viral infection and human papillomavirus type 16 DNA sequences in cervical intraepithelial neoplasia and normal tissue in the west of Scotland: evaluation of treatment policy.Br. Med. J., 296: 381–385, 1988.
19.
NasiellK., NasiellM., VaclavinkovaV.: Behavior of moderate cervical dysplasia during long-term follow-up.Obstet. Gynecol., 61: 609–611, 1983.
20.
NasiellK., RogerV., NasiellM.: Behavior of mild cervical dysplasia during long-term follow-up.Obstet. Gynecol.67: 665–669, 1986.
21.
PennaC., FallaniM.G., BraccoG.L., CioffiM., GordigianiR., MaggiorelliM., MarchionniM.: Il beta-interferone nel trattamento della condilomatosi genitale.Rivista di Ostetricia e Ginecologia, 6: 240–243, 1990.
22.
ShoenfeldA., LevaviA., NitkeS., RevelM., DoernerT.: Treatment of condylomata acuminata (genital warts) with human fibroblast interferon (Frone-inter-Yeda) by intralesional and intramuscular injections and with P.E.G. cream. X World Congress of Gynecology and Obstetrics, San Francisco, California USA, October 1982 (Abstr.).
23.
StefanonB.: Activity of interferon-beta in small condylomatous lesions of the uterine cervix.The Cervix1: 23–26. 1983.
24.
SyrjanenK.J.: Biology of human papillomavirous (HPV) infections and their role in squamous cell carcinogenesis.Med. Biol.65: 21–39, 1987.
25.
SyrjanenK.J.: Human papillomavirus (HPV) lesions in association with cervical dysplasias and neoplasias.Obstet Gynecol., 62: 617–624, 1983.
26.
SyrjanenK., MantyjarviR., SaarikoskiS.: Factors associated with progression of cervical human papillomavirus (HPV) infections into carcinoma in situ during a long-term prospective follow-up.Br. J. Obstet. Gynaecol., 95: 1096–1102, 1988.
27.
SyrjanenK., VayrynenM., MantyjarviR.: Natural history of HPV infections in uterine cervix as determinated by prospective follow-up. In Papilloma Viruses: Molecular and Clinical Aspects (HolewyP.M., & BrokerT.R. (Eds.), UCLA Symposia on Molecular and Cellular Biology, Alan R. Liss, New Work New Series, 32: 31–45, 1985.
28.
TrinchieriG., SantoliD., DeeR.R.: Antiviral activity induced by culturing lymphocytes with tumor derived or virus transformed cells. Identification of the antiviral activity as interferon and characterization of the human effector lymphocyte subpopulation.J. Exp. Med., 147: 1299–1313, 1987.
29.
VasilyevR.V., BokhmanJa, SmorodintsevA.A.: An experience with application of human leucocyte interferon for cervical cancer treatment.Eur. J. Gynaec. Oncol., 4: 313–317, 1990.
